<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[hiv virus Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/hiv+virus.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to hiv virus]]></description>
	<s:counts start="0" returned="20" found="49" />
	<language>en-us</language>
	<item>
		<title><![CDATA[FDA Offers Pfizer's HIV Drug Selzentry New Life -- For All the Good It Will Do]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005550/fda-offers-pfizers-hiv-drug-selzentry-new-life-for-all-the-good-it-will-do/]]></link>
		<description><![CDATA[The FDA approved Pfizer's anti-HIV drug Selzentry for expanded use in combination with other antiretroviral agents for treatment-naÃƒÂ¯ve patients who are infected with only CCR5-tropic HIV-1. Contrary to company expectations, perceived limitations of this entry inhibitor could stall efforts to facilitate usage beyond salvage therapy. by David Phillips]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 30 Nov 2009 10:57:52 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Abbott Q3: How a Monopoly Over an HIV Drug Resulted in Lower Sales]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004809/abbott-q3-how-a-monopoly-over-an-hiv-drug-resulted-in-lower-sales/]]></link>
		<description><![CDATA[A court decision recently put a stamp of approval on Abbott's monopoly over Norvir, a protease inhibitor that functions as a booster for its HIV drug, Kaletra. But that now-legal monopoly has not resulted in increased sales, according to Abbott's Q3 2009 earnings report. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 14 Oct 2009 12:49:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/monopoly.html"><![CDATA[Monopoly]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Hemophiliacs Appeal Ruling That Prevents Them Suing Bayer Over HIV-Tainted Blood]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004780/haemophiliacs-appeal-ruling-that-prevents-them-suing-bayer-over-hiv-tainted-blood/]]></link>
		<description><![CDATA[Taiwanese haemophiliacs who allege they received HIV-tainted blood products from a unit of Bayer are appealing a decision by a U.S. court that they cannot sue in America. Their claims are "dramatic," according to the Guardian. Bayer bought a company called Cutter, which made blood products for haemophiliacs: by Jim...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 13 Oct 2009 08:59:34 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="tickers">BAYR Y</category>
	</item>
	<item>
		<title><![CDATA[Allergan's "Botox Parties" Could Spread HIV as Single-Use Vials Are Re-Used, Suit Claims]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004611/allergans-botox-parties-could-spread-hiv-as-single-use-vials-are-re-used-suit-claims/]]></link>
		<description><![CDATA[Allergan pushes "Botox parties" that put people at risk of HIV and Hepatitis because a "single-use" vial of the drug is used multiple times on different guests, according to a federal lawsuit filed in California. Doctors can only make a profit using Botox if they re-use the "single-use" vials that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 05 Oct 2009 08:03:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/allergan+inc..html"><![CDATA[Allergan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AGN</category>
		<category domain="tickers">AGN</category>
	</item>
	<item>
		<title><![CDATA[Merck CEO Clark Subject of "Wanted" Poster Over Price of HIV Drugs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004154/merck-ceo-clark-subject-of-wanted-poster-over-price-of-hiv-drugs/]]></link>
		<description><![CDATA[The AIDS Healthcare Foundation, which claims to be the U.S.'s largest provider of HIV medicine, has published a "Wanted" poster featuring Merck CEO Richard Clark to protest the "criminal" high price of Isentress. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 08 Sep 2009 14:50:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Bayer Says It Settled Decades-Old HIV-Tainted Blood Cases]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003424/bayer-says-it-settled-decades-old-hiv-tainted-blood-cases/]]></link>
		<description><![CDATA[Bayer says it has entered into a settlement with "the vast majority" of plaintiffs in a decades-old piece of litigation brought by hemophiliacs who were infected with HIV-tainted blood transfusions in the 1980s. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 03 Aug 2009 13:31:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bayer+ag.html"><![CDATA[Bayer AG]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BAYR Y</category>
		<category domain="tickers">BAYR Y</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences Inc., Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-290687.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Operator Instructions.  Our first question comes from the line of Mark Schoenebaum - Deutsche Bank. Mark Schoenebaum - Deutsche Bank Was the French reimbursement approval embedded into your prior product sales guidance and can you repeat what percent of EU that is? Kevin Young...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 21 Apr 2009 19:39:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/deutsche+bank+ag.html"><![CDATA[Deutsche Bank AG]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/adap.html"><![CDATA[ADAP]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">DB,GILD</category>
	</item>
	<item>
		<title><![CDATA[With New CV Drugs, Gilead Tests Its Commitment to Efficiency]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001589/with-new-cv-drugs-gilead-tests-its-commitment-to-efficiency/]]></link>
		<description><![CDATA[Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan.    Combined with Gilead's purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 03 Apr 2009 12:11:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/darusentan.html"><![CDATA[Darusentan]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/ranexa.html"><![CDATA[Ranexa]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[EMD Serono Snags US license for Tesamorelin From Theratechnologies]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F103241-emd-serono-snags-us-license-for-tesamorelin-from-theratechnologies%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:   Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Oct 2008 03:44:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/commercialization.html"><![CDATA[Commercialization]]></category>
		<category domain="http://resources.bnet.com/topic/serono+s.a..html"><![CDATA[Serono S.A.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/tesamorelin.html"><![CDATA[Tesamorelin]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/theratechnologies.html"><![CDATA[Theratechnologies]]></category>
		<category domain="http://resources.bnet.com/topic/service+management.html"><![CDATA[Service Management]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
	</item>
	<item>
		<title><![CDATA[ItÃ¢â‚¬â„¢s Good News, Bad News for GileadÃ¢â‚¬â„¢s HIV Pill]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000161/it%e2%80%99s-good-news-bad-news-for-gilead%e2%80%99s-hiv-pill/]]></link>
		<description><![CDATA[The good news: The FDA approved Viread, GileadÃ¢â‚¬â„¢s dwindling HIV treatment, as a therapy for hepatitis B. The drugÃ¢â‚¬â„¢s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including GileadÃ¢â‚¬â„¢s own Atripla, which includes Viread -- eroded the market for standalone...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 12 Aug 2008 09:37:06 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/shareholder.html"><![CDATA[Shareholder]]></category>
		<category domain="http://resources.bnet.com/topic/viread.html"><![CDATA[Viread]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Cost, Affordability and Cost-Effectiveness of Strategies to Control Tuberculosis in Countries With High HIV Prevalence]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=159593]]></link>
		<description><![CDATA[The HIV epidemic has caused a dramatic increase in Tuberculosis TB in East and southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when budget constraints exist. However, published cost and...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 12 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+epidemic.html"><![CDATA[HIV Epidemic]]></category>
		<category domain="http://resources.bnet.com/topic/tb.html"><![CDATA[TB]]></category>
	</item>
	<item>
		<title><![CDATA[Attracting a Positive Market]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=158935]]></link>
		<description><![CDATA[HIV treatment medications must confront a difficult subject and still offer hope. The ads for HIV treatment medications can be found throughout the urban landscape, decorating a phone booth here, a billboard there, adding to a general acceptance of medical information in the public sphere. So how do companies position...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 17 Oct 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/treatment+medication.html"><![CDATA[Treatment Medication]]></category>
	</item>
	<item>
		<title><![CDATA[Audio Computer-Assisted Self-Interviewing (ACASI) May Avert Socially Desirable Responses About Infant Feeding in the Context of HIV]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=155272]]></link>
		<description><![CDATA[Understanding infant feeding practices in the context of HIV and factors that put mothers at risk of HIV infection is an important step towards prevention of mother to child transmission of HIV PMTCT. Face-to-face FTF interviewing may not be a suitable way of ascertaining this information because respondents may report...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 02 Aug 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/audio.html"><![CDATA[Audio]]></category>
		<category domain="http://resources.bnet.com/topic/biomed+central.html"><![CDATA[BioMed Central]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/computer.html"><![CDATA[Computer]]></category>
	</item>
	<item>
		<title><![CDATA[Cost-Effective Allocation of Government Funds to Prevent HIV Infection]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=153222]]></link>
		<description><![CDATA[Relative to the magnitude of the epidemic, government funds available for HIV prevention are scarce. To optimize use of funds, the paper applies a mathematical model of the cost of HIV prevention interventions using national data on HIV risk-group size and HIV prevalence. This procedure suggested an allocation of funds...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 01 Aug 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[Infection]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/intervention.html"><![CDATA[Intervention]]></category>
		<category domain="http://resources.bnet.com/topic/allocation.html"><![CDATA[Allocation]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
	</item>
	<item>
		<title><![CDATA[An HIV Vaccine: As We Build It, Will They Come?]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=153714]]></link>
		<description><![CDATA[Early researchers accurately predicted that AIDS would have a globally destructive impact. However, other experts erroneously believed that they would be able to develop a vaccine against the virus in a relatively short period. More than twenty years later, scientists continue to work to achieve this goal. This paper addresses...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Wed, 01 Jun 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/researcher.html"><![CDATA[Researcher]]></category>
		<category domain="http://resources.bnet.com/topic/public+health.html"><![CDATA[Public Health]]></category>
		<category domain="http://resources.bnet.com/topic/project+hope.html"><![CDATA[Project HOPE]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
	</item>
	<item>
		<title><![CDATA[Good Governance and Good Health: The Role of Societal Structures in the Human Immunodeficiency Virus Pandemic]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=153869]]></link>
		<description><![CDATA[It has been argued that famine only occurs in nations that are immune to the political will of their people. Political freedom in famine free countries is additionally coupled, albeit unevenly, to other freedoms such as education, health, the control of family size and the ability to seek employment. This...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 25 Apr 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biomed+central.html"><![CDATA[BioMed Central]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/famine.html"><![CDATA[Famine]]></category>
		<category domain="http://resources.bnet.com/topic/vertical+industries.html"><![CDATA[Vertical Industries]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/enterprise+software.html"><![CDATA[Enterprise Software]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
	</item>
	<item>
		<title><![CDATA[Technology, Monopoly, and the Decline of the Viatical Settlements Industry]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=130095]]></link>
		<description><![CDATA[The viatical settlement industry provides an opportunity for terminally-ill consumers, typically HIV patients, to exploit a previously untapped source of equity in existing life insurance contracts to finance consumption and medical expenses. The paper distinguishes two explanations for falling prices-an increase in market power, and a change in market expectations...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Mar 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/national+bureau+of+economic+research.html"><![CDATA[National Bureau Of Economic Research]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[Settlement]]></category>
	</item>
	<item>
		<title><![CDATA[HHS: Efforts to Research and Inform the Public About Nonoxynol-9 and HIV]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=147749]]></link>
		<description><![CDATA[Preventing the transmission of HIV, the virus that causes AIDS, is an important public health challenge. In the mid-1980s, researchers found that Nonoxynol-9 (N-9), a spermicide found in various contraceptive products, showed potential as a microbicide. The report reviews the efforts by federal agencies and manufacturers of contraceptive products to...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Mar 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+health+and+human+services.html"><![CDATA[U.S. Department Of Health And Human Services]]></category>
		<category domain="http://resources.bnet.com/topic/general+accounting+office.html"><![CDATA[General Accounting Office]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
	</item>
	<item>
		<title><![CDATA[HIV Testing Among Indigent Women: Who Gets Tested?]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=128162]]></link>
		<description><![CDATA[AIDS is currently among the ten leading causes of death for women of reproductive age and the leading cause of death for African American women between the ages of 25 and 34, according to the Centers for Disease Control, which advocates recommending and routinely providing testing and counseling in settings...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 14 Feb 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/women.html"><![CDATA[Women]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/aids.html"><![CDATA[AIDS]]></category>
		<category domain="http://resources.bnet.com/topic/gender+and+diversity.html"><![CDATA[Gender And Diversity]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
	</item>
	<item>
		<title><![CDATA[Manufacturing An HIV Vaccine: Policy Issues And Options]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=321758]]></link>
		<description><![CDATA[As product development moves forward, a key question for vaccine developers is whether a promising vaccine concept can actually be produced effectively and affordably as a candidate vaccine. The design and implementation of a vaccine manufacturing process - known as "bioprocess development" - requires a wide range of chemical and...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Tue, 01 Feb 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[Vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/international+aids+vaccine+initiative.html"><![CDATA[International AIDS Vaccine Initiative]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
	</item>
</channel>
</rss>
